SLFN11-mediated TRNA Regulation Induces Cell Death by Disrupting Proteostasis in Response to DNA-damaging Agents

Overview

Journal bioRxiv

Date 2025 Jan 20

PMID 39829761

Authors

Yuki Iimori

Teppei Morita

Takeshi Masuda

Shojiro Kitajima

Nobuaki Kono

Shun Kageyama

Josephine Galipon

Atsuo T Sasaki

Akio Kanai

Affiliations

Soon will be listed here.

Abstract

DNA-damaging agents (DDAs) have long been used in cancer therapy. However, the precise mechanisms by which DDAs induce cell death are not fully understood and drug resistance remains a major clinical challenge. Schlafen 11 (SLFN11) was identified as the gene most strongly correlated with the sensitivity to DDAs based on mRNA expression levels. SLFN11 sensitizes cancer cells to DDAs by cleaving and downregulating tRNA(TAA). Elucidating the detailed mechanism by which SLFN11 induces cell death is expected to provide insights into overcoming drug resistance. Here, we show that, upon administration of DDAs, SLFN11 cleaves tRNA(TAA), leading to ER stress and subsequent cell death regulated by inositol-requiring enzyme 1 alpha (IRE1α). These responses were significantly alleviated by SLFN11 knockout or transfection of tRNA(TAA). Our proteomic analysis suggests that tRNA(TAA) influences proteins essential for maintaining proteostasis, especially those involved in ubiquitin-dependent proteolysis. Additionally, we identified the cleavage sites of tRNA(TAA) generated by SLFN11 in cells, and revealed that tRNA fragments contribute to ER stress and cell death. These findings suggest that SLFN11 plays a crucial role in proteostasis by regulating tRNAs, and thus determines cell fate under DDA treatment. Consequently, targeting SLFN11-mediated tRNA regulation could offer a novel approach to improve cancer therapy.

References

Murai Y, Jo U, Murai J, Jenkins L, Huang S, Chakka S . SLFN11 Inactivation Induces Proteotoxic Stress and Sensitizes Cancer Cells to Ubiquitin Activating Enzyme Inhibitor TAK-243. Cancer Res. 2021; 81(11):3067-3078. PMC: 8178208. DOI: 10.1158/0008-5472.CAN-20-2694. View

Zhang B, Ramkumar K, Cardnell R, Gay C, Stewart C, Wang W . A wake-up call for cancer DNA damage: the role of Schlafen 11 (SLFN11) across multiple cancers. Br J Cancer. 2021; 125(10):1333-1340. PMC: 8576031. DOI: 10.1038/s41416-021-01476-w. View

Carreras-Sureda A, Kroemer G, Cardenas J, Hetz C . Balancing energy and protein homeostasis at ER-mitochondria contact sites. Sci Signal. 2022; 15(741):eabm7524. DOI: 10.1126/scisignal.abm7524. View

Thrun A, Garzia A, Kigoshi-Tansho Y, Patil P, Umbaugh C, Dallinger T . Convergence of mammalian RQC and C-end rule proteolytic pathways via alanine tailing. Mol Cell. 2021; 81(10):2112-2122.e7. PMC: 8141035. DOI: 10.1016/j.molcel.2021.03.004. View

Zoppoli G, Regairaz M, Leo E, Reinhold W, Varma S, Ballestrero A . Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents. Proc Natl Acad Sci U S A. 2012; 109(37):15030-5. PMC: 3443151. DOI: 10.1073/pnas.1205943109. View

Lee S, Hoyt S, Wu X, Garvie C, McGaunn J, Shekhar M . Velcrin-induced selective cleavage of tRNA(TAA) by SLFN12 causes cancer cell death. Nat Chem Biol. 2022; 19(3):301-310. DOI: 10.1038/s41589-022-01170-9. View

Mu X, Hur S . Immunogenicity of -Transcribed RNA. Acc Chem Res. 2021; 54(21):4012-4023. PMC: 9127547. DOI: 10.1021/acs.accounts.1c00521. View

Fujiwara K, Maekawa M, Iimori Y, Ogawa A, Urano T, Kono N . The crucial role of single-stranded DNA binding in enhancing sensitivity to DNA-damaging agents for Schlafen 11 and Schlafen 13. iScience. 2023; 26(12):108529. PMC: 10730379. DOI: 10.1016/j.isci.2023.108529. View

Murai J, Tang S, Leo E, Baechler S, Redon C, Zhang H . SLFN11 Blocks Stressed Replication Forks Independently of ATR. Mol Cell. 2018; 69(3):371-384.e6. PMC: 5802881. DOI: 10.1016/j.molcel.2018.01.012. View

10.

Li M, Kao E, Gao X, Sandig H, Limmer K, Pavon-Eternod M . Codon-usage-based inhibition of HIV protein synthesis by human schlafen 11. Nature. 2012; 491(7422):125-8. PMC: 3705913. DOI: 10.1038/nature11433. View

11.

Udagawa T, Seki M, Okuyama T, Adachi S, Natsume T, Noguchi T . Failure to Degrade CAT-Tailed Proteins Disrupts Neuronal Morphogenesis and Cell Survival. Cell Rep. 2021; 34(1):108599. DOI: 10.1016/j.celrep.2020.108599. View

12.

Sprinzl M, Horn C, Brown M, Ioudovitch A, Steinberg S . Compilation of tRNA sequences and sequences of tRNA genes. Nucleic Acids Res. 1998; 26(1):148-53. PMC: 147216. DOI: 10.1093/nar/26.1.148. View

13.

Jitobaom K, Sirihongthong T, Boonarkart C, Phakaratsakul S, Suptawiwat O, Auewarakul P . Human Schlafen 11 inhibits influenza A virus production. Virus Res. 2023; 334:199162. PMC: 10410578. DOI: 10.1016/j.virusres.2023.199162. View

14.

Omar I, Lapenna A, Cohen-Daniel L, Tirosh B, Berger M . Schlafen2 mutation unravels a role for chronic ER stress in the loss of T cell quiescence. Oncotarget. 2016; 7(26):39396-39407. PMC: 5129940. DOI: 10.18632/oncotarget.9818. View

15.

Kochavi A, Nagel R, Korner P, Bleijerveld O, Lin C, Huinen Z . Chemotherapeutic agents and leucine deprivation induce codon-biased aberrant protein production in cancer. Nucleic Acids Res. 2024; 52(22):13964-13979. PMC: 11662694. DOI: 10.1093/nar/gkae1110. View

16.

Kciuk M, Marciniak B, Kontek R . Irinotecan-Still an Important Player in Cancer Chemotherapy: A Comprehensive Overview. Int J Mol Sci. 2020; 21(14). PMC: 7404108. DOI: 10.3390/ijms21144919. View

17.

Guo G, Wang Y, Hu X, Li Z, Tan J, Qiao W . Human Schlafen 11 exploits codon preference discrimination to attenuate viral protein synthesis of prototype foamy virus (PFV). Virology. 2021; 555:78-88. DOI: 10.1016/j.virol.2020.12.015. View

18.

Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin A, Kim S . The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012; 483(7391):603-7. PMC: 3320027. DOI: 10.1038/nature11003. View

19.

Izawa T, Park S, Zhao L, Hartl F, Neupert W . Cytosolic Protein Vms1 Links Ribosome Quality Control to Mitochondrial and Cellular Homeostasis. Cell. 2017; 171(4):890-903.e18. DOI: 10.1016/j.cell.2017.10.002. View

20.

de Sousa Cavalcante L, Monteiro G . Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer. Eur J Pharmacol. 2014; 741:8-16. DOI: 10.1016/j.ejphar.2014.07.041. View